Immunotherapy for Alzheimer's disease: From anti-β-amyloid to tau-based immunization strategies

Immunotherapy

Volumn 4, Issue 2, 2012, Pages 213-238

  Panza, Francesco ^a   Frisardi, Vincenza ^a   Solfrizzi, Vincenzo ^a   Imbimbo, Bruno P ^a   Logroscino, Giancarlo ^a   Santamato, Andrea ^a   Greco, Antonio ^a   Seripa, Davide ^a   Pilotto, Alberto ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

.amyloid; active immunotherapy; Alzheimer's disease; bapineuzumab; monoclonal antibody; passive immunotherapy; polyclonal antibody; solanezumab; tau protein

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; BENZOTHIAZOLE; CRENEZUMAB; DAVUNETIDE; DNA VACCINE; EHT 0202; EHT0202; EPOTHILONE A; GANTENERUMAB; IMMUNOGLOBULIN G; LITHIUM; METHYLENE BLUE; NEWGAM; PACLITAXEL; PBT 2; PHOSPHOPROTEIN PHOSPHATASE 2A; PLACEBO; PONEZUMAB; QS 21; RECOMBINANT HUMAN TAU PROTEIN; RECOMBINANT PROTEIN; RHODANINE; SEMAGACESTAT; SOLANEZUMAB; TAU PROTEIN; TIDEGLUSIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY RESPONSE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN STEM; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CONFUSION; DAILY LIFE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DEVELOPMENT; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FOLLOW UP; GAIT DISORDER; HIPPOCAMPUS; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEARNING DISORDER; LONG TERM POTENTIATION; MEMORY; MENINGOENCEPHALITIS; MENTAL PERFORMANCE; MONOTHERAPY; MOTOR CORTEX; MOTOR PERFORMANCE; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PASSIVE IMMUNIZATION; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE DRUG DOSE; SPINAL CORD; TAUOPATHY; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION; VOMITING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN EDEMA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; IMMUNIZATION; TAU PROTEINS;

EID: 84857558439     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.170     Document Type: Review

References (223)

1. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimers disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 11(2), 111-128 (2009).
2. Thies W, Bleiler L; Alzheimers Association. 2011 Alzheimers disease facts and figures. Alzheimers Dement. 7(2), 208-244 (2011).
3. Frisardi V, Solfrizzi V, Imbimbo PB et al. Towards disease-modifying treatment of Alzheimers disease: drugs targeting beta?amyloid. Curr. Alzheimer Res. 7(1), 40-55 (2010).
4. Panza F, Solfrizzi V, Frisardi V et al. Disease-modifying approach to the treatment of Alzheimers disease: from alpha?secretase activators to gamma?secretase inhibitors and modulators. Drugs Aging 26(7), 537-555 (2009).
5. Panza F, Solfrizzi V, Frisardi V et al. Beyond the neurotransmitter- focused approach in treating Alzheimers disease: drugs targeting beta?amyloid and tau protein. Aging Clin. Exp. Res. 21(6), 386-406 (2009).
6. Alzheimer A. On a peculiar disease of the cerebral cortex. Allgemeine Zeitschrift fur Psychiatrie und Psychish-Gerichtlich Medicin 64, 146-148 (1907).
7. Khachaturian ZS. Diagnosis of Alzheimers disease. Arch. Neurol. 42(11), 1097-1105 (1985).
8. Mirra SS, Heyman A, McKeel D et al. The consortium to establish a registry for Alzheimers disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimers disease. Neurology 41(4), 479-486 (1991).
9. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J. Neuropathol. Exp. Neurol. 58(11), 1147-1155 (1999).
10. Su JH, Cummings BJ, Cotman CW. Early phosphorylation of tau in Alzheimers disease occurs at Ser-202 and is preferentially located within neurites. NeuroReport 5(17), 2358-2362 (1994).
11. Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimers disease: I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res. 739(1-2), 79-87 (1996).
12. Graeber MB, Kosel S, Egensperger R et al. Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics 1(1), 73-80 (1997).
13. Small SA, Duff K. Linking Ab and tau in late-onset Alzheimers disease: A dual pathway hypothesis. Neuron 60(4), 534-542 (2008).
14. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimers disease: uncovering the secrets of secretases. Curr. Opin. Neurobiol. 11(5), 585-590 (2001).
15. Seubert P, Vigo-Pelfry C, Esch F et al. Isolation and quantification of soluble Alzheimers b-peptide from biological fluids. Nature 359(6393), 325-327 (1996).
16. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of Ab42(43) and Ab40 in senile plaques with specific Ab monoclonals: Evidence that the initially deposited species is Ab42(43). Neuron 13(1), 45-53 (1993).
17. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimers disease. Trends Pharmacol. Sci. 12(5), 383-388 (1991).
18. Armstrong RA. The pathogenesis of Alzheimers disease: A reevaluation of the "Amyloid Cascade Hypothesis". Int. J. Alzheimers Dis. 2011, 630865 (2011)
19. Giasson BI, Lee VMY, Trojanowski JQ. Interactions of amyloidogenic proteins. Neuromolecular Med. 4(1-2), 49-58 (2003).
20. Smith MA, Siedlak SL, Richey PL et al. Tau protein directly interacts with the amyloid b?protein precursor: Implications for Alzheimers disease. Nat. Med. 1(4), 365-369 (1995).
21. Oyama F, Shimada H, Oyama R, Titani K, Ihara Y. b?amyloid protein precursor and t mRNA levels versus b?amyloid plaque and neurofibrillary tangles in the aged human brain. J. Neurochem. 60(5), 1658-1664 (1993).
22. Shankar GM, Li S, Mehta TH et al. Amyloid-b protein dimers isolated directly from Alzheimers brains impair synaptic plasticity and memory. Nat. Med. 14(8), 837-842 (2008).
23. Selkoe DJ. Soluble oligomers of the amyloid b-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192(1), 106-113 (2008).
24. Koffie RM, Meyer-Luehmann M, Hashimoto T et al. Oligomeric amyloid b associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106(10), 4012-4017 (2009).
25. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloidβ protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27(11), 2866-2875 (2007).
26. Lesnè S, Koh MT, Kotilinek L et al. A specific amyloidβ protein assembly in the brain impairs memory. Nature 440(7082), 352-357 (2006).
27. Imbimbo BP, Panza F, Frisardi V et al. Therapeutic intervention for Alzheimers disease with g?secretase inhibitors: Still a viable option? Expert Opin. Investig. Drugs 20(3), 325-341 (2011).
28. Vellas B, Sol O, Snyder P et al. EHT0202 in Alzheimers disease: A 3?month, randomized, placebo-controlled, double-blind study. Curr. Alzheimer Res. 8(2), 203-212 (2011).
29. Lannfelt, L, Blennow K, Zetterberg H et al.; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimers disease: A Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7(9), 779-786 (2008).
30. Faux NG, Ritchie CW, Gunn A et al. PBT2 rapidly improves cognition in Alzheimers disease: Additional Phase II analyses. J. Alzheimers Dis. 20(2), 509-516 (2010).
31. Wisniewski T, Konietzko U. Amyloid-beta immunisation for Alzheimers disease. Lancet Neurol. 7(9), 805-811 (2008).
32. Cribbs DH. Abeta DNA vaccination for Alzheimers disease: focus on disease prevention. CNS Neurol. Disord. Drug Targets 9(2), 207-216 (2010).
33. Takashima A. TAU aggregation is a therapeutic target for Alzheimers disease. Curr. Alzheimer Res. 7(8), 665-669 (2010).
34. Lace GL, Wharton SB, Ince PG. A brief history of tau: The evolving view of the microtubule-associated protein tau in neurodegenerative diseases. Clin. Neuropathol. 26(2), 43-58 (2007).
35. Clark CM, Xie S, Chittams J et al. Cerebrospinal fluid tau and b?amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol. 60(12), 1696-1702 (2003).
36. Sahara N, Maeda S, Murayama M et al. Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur. J. Neurosci. 25(10), 3020-3029 (2007).
37. Kimura T, Fukuda T, Sahara N et al. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J. Biol. Chem. 285(49), 38692-38699 (2010).
38. Maeda S, Sahara N, Saito Y et al. Granular tau oligomers as intermediates of tau filaments. Biochemistry 46(12), 3856-3861 (2007).
39. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42(3 Pt 1), 631-639 (1992).
40. Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimers disease? J. Clin. Psychiatry 70(6), 919-921 (2009).
41. Medina M. Recent developments in tau-based therapeutics for neurodegenerative diseases. Recent Pat. CNS Drug Discov. 6(1), 20-30 (2011).
42. Haass C, Selkoe DJ. Protein oligomers in neurodegeneration: lessons from the Alzheimers amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8(2), 101-112 (2007).
43. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118(1), 53-69 (2009).
44. Brunden KR, Trojanowski JQ, Lee VM. Advances in tau-focused drug discovery for Alzheimers disease and related tauopathies. Nat. Rev. Drug Discov. 8(10), 783-793 (2009).
45. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci. 25(22), 5446-5454 (2005).
46. de Calignon A, Spires-Jones TL, Pitstick R, Carlson GA, Hyman BT. Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68(7), 757-761 (2009).
47. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimers disease. Expert Rev. Neurother. 10(5), 711-728 (2010).
48. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 59(4-5), 276-289 (2010).
49. Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: Implications for the treatment of tauopathic neurodegenerative diseases. Biochemistry 44(30), 10227-10237 (2005).
50. Pickhardt M, Biernat J, Khlistunova I et al. N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr. Alzheimer Res. 4(4), 397-402 (2007).
51. Bulic B, Pickhardt M, Khlistunova I et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed. Engl. 46(48), 9215-9219 (2007).
52. Pickhardt M, Larbig G, Khlistunova I et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46, 10016-10023 (2007).
53. Pickhardt M, Gazova Z, von Bergen M et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimers paired helical filaments in vitro and in cells. J. Biol. Chem. 280(5), 3628-3635 (2005).
54. Crowe A, Huang W, Ballatore C et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48(32), 7732-7745 (2009).
55. Buchholz K, Schirmer RH, Eubel JK et al. Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrob. Agents Chemother. 52(1), 183-191 (2008).
56. Wischik CM, Bentham P, Wischik DJ, Seng KM. Tau aggregation inhibitor (TAI) therapy with Rember™ arrests disease progression in mild and moderate Alzheimers disease over 50 weeks. Alzheimers Dement. 4(Suppl. 1), T167 (2008).
57. O'Leary JC 3rd, Li Q, Marinec P et al. Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener. 5, 45 (2010).
58. Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: Practical experience from a Phase 2 trial of tau-aggregation inhibitor therapy. J. Nutr. Health Aging 13(4), 367-369 (2009).
59. Staff RT, Ahearn TS, Murray AD et al. Tau aggregation inhibitor (TAI) therapy with Rember™ arrests the trajectory of rCBF decline in brain regions affected by tau pathology in mild and moderate Alzheimers disease (AD). Alzheimers Dement. 4(Suppl. 2), T775 (2008).
60. Murray AD, Staff RT, Ahearn TS et al. Tau aggregation inhibitor (TAI) therapy with Rember™ changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimers disease (AD). Alzheimers Dement. 4(Suppl. 2), T786 (2008).
61. Masuda M, Suzuki N, Taniguchi S et al. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45(19), 6085-6094 (2009).
62. Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5(3), 443-457 (2008).
63. Illenberger S, Zheng-Fischhofer Q, Preuss U et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: Implications for Alzheimers disease. Mol. Biol. Cell 9(6), 1495-1512 (1998).
64. Wen Y, Planel E, Herman M et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3b mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28(10), 2624-2632 (2008).
65. Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 281(35), 25457-25465 (2006).
66. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am. J. Geriatr. Psychiatry 5(4), 344-351 (1997).
67. Porsteinsson AP, Tariot PN, Jakimovich LJ et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry 11(4), 434-440 (2003).
68. Leyhe T, Eschweiler GW, Stransky E et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimers disease. J. Alzheimers Dis. 16(3), 649-656 (2009).
69. Hampel H, Ewers M, Burger K et al. Lithium trial in Alzheimers disease: A randomized, single-blind, placebo-controlled, multicenter 10?week study. J. Clin. Psychiatry 70(6), 922-931 (2009).
70. Tariot PN, Aisen P, Cummings J et al. The ADCS valproate neuroprotection trial: Primary efficacy and safety results. Alzheimers Dement. 5(4), P84-P85 (2009).
71. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15(23), 2321-2328 (2008).
72. Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Gotz J. Reduced protein phosphatise 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem. 276(41), 38193-38200 (2001).
73. Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Paired helical filament-like phosphorylation of tau, deposition of b/A4?amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 69(3), 691-698 (1995).
74. Iqbal K, Alonso Adel C, El-Akkad E et al. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci. 19(1-2), 95-99 (2002).
75. Tanimukai H, Kudo T, Tanaka T, Grundke-Iqbal I, Iqbal K, Takeda M. Novel therapeutic strategies for neurodegenerative disease. Psychogeriatrics 9(2), 103-109 (2009).
76. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimers disease, an early interim report. Exp. Neurol. 223(2), 252-266 (2010).
77. Bassan M, Zamostiano R et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72(3), 1283-1293 (1999).
78. Stewart AJ, Fox A, Morimoto BH, Gozes I. Looking for novel ways to treat the hallmarks of Alzheimers disease. Expert Opin. Investig. Drugs 16(8), 1183-1196 (2007).
79. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 293(3), 1091-1098 (2000).
80. Kennedy GJ, Golde TE, Tariot PN, Cummings JL. Amyloid-based interventions in Alzheimers disease. CNS Spectr. 12(Suppl. 1), 1-14 (2007).
81. Schenk D, Barbour R, Dunn W et al. Immunization with amyloidβ attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740), 173-177 (1999).
82. Morgan D, Diamond D, Gottschall P et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimers disease. Nature 408(6815), 982-985 (2000).
83. Wang CM, Devries S, Camboni M, Glass M, Martin PT. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimers disease. Neurobiol. Dis. 39(3), 409-422 (2010).
84. Wiessner C, Wiederhold KH, Tissot AC et al. The second-generation active Ab immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J. Neurosci. 31(25), 9323-9331 (2011).
85. Sigurdsson EM, Scholtzova H, Mehta P, Frangione B, Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloidβ homologous peptide reduces Alzheimers disease associated pathology in transgenic mice. Am. J. Pathol. 159(2), 439-447 (2001).
86. Maier M, Seabrook TJ, Lazo ND et al. Short amyloid beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimers disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 26(18), 4717-4728 (2006).
87. Frenkel D, Katz O, Solomon B. Immunization against Alzheimers beta ?amyloid plaques via EFRH phage administration. Proc. Natl Acad. Sci. USA 97(21), 11455-11459 (2000).
88. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6(8), 916-919 (2000).
89. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Ab(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimers disease. PLoS ONE 6(4), E18296 (2011).
90. Bacskai BJ, Kajdasz ST, Christie RH et al. Imaging of amyloidβ deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7(3), 369-372 (2001).
91. Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer b?amyloid peptide. Proc. Natl Acad. Sci. USA 93(1), 452-455 (1996).
92. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J. Neurosci. 23(24), 8532-8538 (2003).
93. Sigurdsson EM, Knudsen E, Asuni A et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimers disease mouse model immunized with amyloidβ derivatives. J. Neurosci. 24(28), 6277-6282 (2004).
94. Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 31, 175-193 (2008).
95. Rosenmann H, Grigoriadis N, Karussis D et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63(10), 1459-1467 (2006).
96. Boimel M, Grigoriadis N, Lourbopoulos A et al. Efficacy safety of immunization with phosphorylated tau against neurofibrillary and tangles in mice. Exp. Neurol. 224(2), 472-485 (2010).
97. Novak M. Tau vaccine: Active immunization with misfloded tau protein attenuates tau pathology in the transgenic rat model of tauopathy. Alzheimers Dement. 5(Suppl. 1), P93 (2009) (Abstract).
98. Zilka N, Kontsekova E, Novak M. Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J. Alzheimers Dis. 15(2), 169-179 (2008).
99. Kontsekova E, Ivanovova N, Handzusova M, Novak M. Chaperone-like antibodies in neurodegenerative tauopathies: Implication for immunotherapy. Cell. Mol. Neurobiol. 29(6-7), 793-798 (2009).
100. Bretteville A, Planel E. Tau aggregates: Toxic, inert, or protective species? J. Alzheimers Dis. 14(4), 431-436 (2008).
101. Congdon EE, Duff KE. Is tau aggregation toxic or protective? J. Alzheimers Dis. 14(4), 453-457 (2008).
102. Kayed R, Jackson GR. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr. Opin. Immunol. 21(3), 359-363 (2009)
103. Walsh DM, Selkoe DJ. Abeta oligomers - a decade of discovery. J. Neurochem. 101(5), 1172-1184 (2007).
104. Bayer AJ, Bullock R, Jones RW et al. Evaluation of the safety and immunogenicity of synthetic Ab42 (AN1792) in patients with AD. Neurology 64(1), 94-101 (2005).
105. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimers disease: Clinical investigations into AN1792- associated meningoencephalitis. Neurodegener. Dis. 5(3-4), 194-196 (2008).
106. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1), 46-54 (2003).
107. Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F. Neuropathology and pathogenesis of encephalitis following amyloid?beta immunization in Alzheimers disease. Brain Pathol. 14(1), 11-20 (2004).
108. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid?beta peptide. a case report. Nat. Med. 9(4), 448?452 (2003).
109. Fisher Y, Nemirovsky A, Baron R, Monsonego A. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimers disease. PLoS ONE 26, 5(5), E10830 (2010).
110. Bombois S, Maurage CA, Gompel M et al. Absence of beta?amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch. Neurol. 64(4), 583-587 (2007).
111. Masliah E, Hansen L, Adame A et al. Ab vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64(1), 129-131 (2005).
112. Hock C, Konietzko U, Streffer JR et al. Antibodies against b-amyloid slow cognitive decline in Alzheimers disease. Neuron 38(4), 547-554 (2003).
113. Holmes C, Boche D, Wilkinson D et al. Long-term effects of Ab42 immunisation in Alzheimers disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet 372(9634), 216-223 (2008).
114. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Ab42 fibrils. Science 293(5534), 1491-1495 (2001).
115. Knopman DS, Parisi JE, Salviati A et al. Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62(11), 1087-1095 (2003).
116. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3), 321-332 (2004).
117. Tabira T. Immunization therapy for Alzheimer disease: A comprehensive review of active immunization strategies. Tohoku J. Exp. Med. 220(2), 95-106 (2010).
118. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid?beta immunotherapy? Nat. Rev. Neurol. 6(2), 108-119 (2010).
119. Das P, Murphy M, Younkin L, Younkin S, Golde T. Reduced effectiveness of Ab1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22(5), 721-727 (2010).
120. Frenkel D, Dewachter I, van Leuven F, Solomon B. Reduction of b?amyloid plaques in brain of transgenic mouse model of Alzheimers disease by EFRH-phage immunization. Vaccine 21(11-12), 1060-1065 (2003).
121. Agadjanyan MG, Ghochikyan A, Petrushina I et al. Prototype Alzheimers disease vaccine using the immunodominant B cell epitope from b?amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174(3), 1580-1586 (2005).
122. Petrushina I, Ghochikyan A, Mktrichyan M et al. Alzheimers disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Ab species in amyloid precursor protein transgenic mice. J. Neurosci. 27(46), 12721-12731 (2007).
123. Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ Jr, Federoff HJ. HSV amplicon-mediated Ab vaccination in Tg2576 mice: differential antigenspecific immune responses. Neurobiol. Aging 26(4), 393-407 (2005).
124. Okura Y, Miyakoshi A, Kohyama K, Park IK, Staufenbiel M, Matsumoto Y. Nonviral Abeta DNA vaccine therapy against Alzheimers disease: long-term effects and safety. Proc. Natl Acad. Sci. USA 103(25), 9619-9624 (2006).
125. Movsesyan N, Ghochikyan A, Mkrtichyan M et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine-a novel immunotherapeutic strategy. PLoS ONE 3, E2124 (2008).
126. Bach P, Tschäpe JA, Kopietz F et al. Vaccination with Ab-displaying virus-like particles reduces soluble and insoluble cerebral Ab and lowers plaque burden in APP transgenic mice. J. Immunol. 182(12), 7613-7624 (2008).
127. Lemere CA, Maron R, Spooner ET et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. NY Acad. Sci. 920, 328-331 (2000).
128. Zhang J, Wu X, Qin C et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta?amyloid plaques in a mouse model of Alzheimers disease. Neurobiol. Dis. 14(3), 365-379 (2003).
129. Frenkel D, Puckett L, Petrovic S et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol. 63(5), 591?601(2008).
130. Weiner HL, Lemere CA, Maron R et al. Nasal administration of amyloidβ peptide decreases cerebral amyloid burden in a mouse model of Alzheimers disease. Ann. Neurol. 48(4), 567-579 (2000).
131. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27(34), 9115-9129 (2007).
132. Lewis J, McGowan E, Rockwood J et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 5(4), 402-405 (2000).
133. Rosenmann H, Grigoriadis N, Eldar-Levy H et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 212(1), 71?78 (2008).
134. Sigurdsson EM, Quatermain D, Boutajangout A. Tau immunotherapy prevents cognitive decline and clears pathological tau in a tangle mouse model. Alzheimeirs Dement. 4(Suppl. 1), T191 (2008).
135. Khrisnamurthy PK, Sait HBR, Boutajangout A, Sigurdsson EM. Immunotherapy targeting Alzheimers phosphor-tau epitope within the microtubule binding region of tau clears pathological tau and prevents functional decline in a mouse model of tauopathy. Alzheimeirs Dement. 5(Suppl. 1), P112 (2009).
136. Andorfer C, Kress Y, Espinoza M et al. Hyperphosphsorylation and aggregation of tau in mice expressing normal human tau isoforms. J. Neurochem. 86(3), 582-590 (2003).
137. Boutajangout A, Frangione B, Brion JP, Wisniewsky T, Sigurdsson EM. Presenilin 1 mutation promotes tau phosphorylation and aggregation in a novel Alzheimers disease mouse model. Alzheimeirs Dement. 4(Suppl. 1), T185 (2008).
138. Wisniewski T, Sigurdsson EM. Murine models of Alzheimers disease and their use in developing immunotherapies. Biochim. Biophys. Acta 1802(10), 847-859 (2010).
139. Kayed R. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. Hum. Vaccin. 6(11), 931-935 (2010).
140. Jicha GA. Is passive immunization for Alzheimers disease 'alive and well' or 'dead and buried'? Expert Opin. Biol. Ther. 9, 481-491 (2009).
141. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against βamyloid (Ab) for the treatment of Alzheimers disease: The Ab target at a crossroads. Expert Opin. Biol. Ther. 11(6), 679-686 (2011).
142. Morgan D. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener. Dis. 2(5), 261-266 (2005).
143. Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimers research: Safety, pharmacokinetics, metabolism, and analytical tools. J. Neurochem. 104(4), 859-874 (2008).
144. Walsh DM, Selkoe DJ. Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 11(4), 213-228 (2004).
145. Kerchner GA, Boxer AL. Bapineuzumab. Expert Opin. Biol. Ther. 10(7), 1121-1130 (2010).
146. Panza F, Frisardi V, Imbimbo BP et al. Bapineuzumab: Anti-βamyloid monoclonal antibodies for the treatment of Alzheimers disease. Immunotherapy 2(6), 767-782 (2010).
147. Panza F, Frisardi V, Imbimbo BP et al. Anti-b-Amyloid immunotherapy for Alzheimers disease: focus on bapineuzumab. Curr. Alzheimer Res. 8(8), 808-817 (2011).
148. Samadi H, Sultzer D. Solanezumab for Alzheimers disease. Expert Opin. Biol. Ther. 11(6), 787-798 (2011).
149. Pul R, Dodel R, Stangel M. Antibody-based therapy in Alzheimers disease. Expert Opin. Biol. Ther. 11(3), 343-357 (2011).
150. Mamikonyan G, Necula M, Mkrtichyan M et al. Anti-A beta1-11 antibody binds to different beta?amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J. Biol. Chem. 282(31), 22376-22386 (2007).
151. Bacskai BJ, Kajdasz ST, McLellan ME et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid?beta in vivo by immunotherapy. J. Neurosci. 22(18), 7873-7878 (2002).
152. Tamura Y, Hamajima K, Matsui K et al. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol. Dis. 20(2), 541-549 (2005)
153. Johnson-Wood K, Lee M, Motter R et al. Amyloid precursor protein processing and Abeta42 deposition in a transgenic mouse model of Alzheimers disease. Proc. Natl Acad. Sci. USA 94(4), 1550-1555 (1997).
154. Black RS, Sperling RA, Safirstein B et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis. Assoc. Disord. 24(2), 198-203 (2010).
155. Salloway S, Sperling R, Gilman S et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73(24), 2061-2070 (2009).
156. Rinne JO, Brooks DJ, Rossor MN et al. 11C?PiB PET assessment of change in fibrillar amyloid?beta load in patients with Alzheimers disease treated with bapineuzumab: A Phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9(4), 363-372 (2010).
157. Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behav. Neurol. 21(1), 117-128 (2009).
158. Blennow K, Zetterberg H, Wei J, Liu E, Black R, Grundman M. Immunotherapy with bapineuzumab lowers CSF tau protein levels in patients with Alzheimers disease. Alzheimers Dement. 6(Suppl.), S134-S135 (2010).
159. Laskowitz DT, Vitek MP. Apolipoprotein E and neurological disease: Therapeutic potential and pharmacogenomic interactions. Pharmacogenomics 8(8), 959-969 (2008).
160. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimers disease. Neuron 63(3), 287-303 (2009).
161. Laskowitz DT, Thekdi AD, Thekdi SD et al. Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp. Neurol. 167(1), 74-85 (2001).
162. Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimers disease or mild cognitive impairment? Front. Aging Neurosci. 2, PII19 (2010)
163. Atwood CS, Bishop GM, Perry G, Smith MA. Amyloid-beta: A vascular sealant that protects against hemorrhage? J. Neurosci. Res. 70(3), 356 (2002)
164. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM. The cerebral beta?amyloid angiopathies: hereditary and sporadic. Brain Pathol. 16(1), 30-39 (2006).
165. Pfeifer M, Boncristiano S, Bondolfi L et al. Cerebral hemorrhage after passive anti-Ab immunotherapy. Science 298(5597), 1379 (2002).
166. Racke MM, Boone LI, Hepburn DL et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyoid beta. J. Neurosci. 25(3), 629-636 (2005).
167. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN. Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144(3), 950-960 (2007).
168. Boche D, Zotova E, Weller RO et al. Consequence of Abeta immunization on the vasculature of human Alzheimers disease brain. Brain 131(Pt 12), 3299?3310 (2008).
169. Patton RL, Kalback WM, Esh CL et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimers disease patients: A biochemical analysis. Am. J. Pathol. 169(3), 1048-1063 (2006).
170. Vellas B, Black R, Thal LJ et al.; AN1792 (QS?21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody responders. Curr. Alzheimer Res. 6(2), 144-151 (2009).
171. Seubert P, Vigo-Pelfrey C, Esch F et al. Isolation and quantification of
172. Siemers ER, Friedrich S, Dean RA et al. Safety and changes in plasma and cerebrospinal fluid amyloid?beta after a single administration of an amyloid?beta monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol. 33(2), 67-73 (2010).
173. DeMattos RB, Racke MM, Gelfanova V et al. Identification, characterization, and comparison of amino-terminally truncated Abeta42 peptides in Alzheimers disease brain tissue and in plasma from Alzheimers patients receiving solanezumab immunotherapy treatment. Alzheimers Dement. 5, P156-P157 (2009).
174. Seubert P, Barbour R, Khan K et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener. Dis. 5(2), 65-71 (2008).
175. DeMattos RB, Bales KR, Cummins DJ et al. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimers disease. Proc. Natl Acad. Sci. USA 98(15), 8850-8855 (2001).
176. Dodart JC, Bales KR, Gannon KS et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimers disease model. Nat. Neurosci. 5(5), 452-457 (2002).
177. DeMattos RB, Bales KR, Cummins DJ et al. Brain to plasma amyloid?beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimers disease. Science 295(5563), 2264-2267 (2002).
178. Levites Y, Smithson LA, Price RW et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimers disease mouse models. FASEB J. 20(14), 2576-2578 (2006).
179. Yamada K, Yabuki C, Seubert P et al. Abeta immunotherapy: Intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J. Neurosci. 29(36), 11393-11398 (2009).
180. Siemers ER, Friedrich S, Dean RA et al. P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimers disease. Alzheimers Dement. 4, T774 (2008).
181. Racke MM, Boone LI, Hepburn DL et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J. Neurosci. 25(3), 629-636 (2005).
182. Schroeter S, Khan K, Barbour R et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28(27), 6787-6793 (2008).
183. Nicholas T, Knebel W, Gastonguay MR et al. Preliminary population pharmacokinetic modeling of PF?04360365, a humanized anti?amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimers disease. Alzheimers Dement. 5, P253 (2009).
184. Watts RJ, Chen M, Atwal J et al. Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo. Alzheimers Dement. 5, P426 (2009).
185. Relkin NR. Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin. Alzheimers Dement. 4, T101 (2008).
186. Dodel R, Hampel H, Depboylu C et al. Human antibodies against amyloid beta peptide: A potential treatment for Alzheimers disease. Ann. Neurol. 52(2), 253-256 (2002).
187. Du Y, Dodel R, Hampel H et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57(5), 801-805 (2001).
188. Britschgi M, Olin CE, Johns HT et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimers disease. Proc. Natl Acad. Sci. USA 106(29), 12145-12150 (2009).
189. Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloidβ peptide. J. Neurosci. Res. 84(2), 434-443 (2006).
190. Du Y, Wei X, Dodel R et al. Human anti-βamyloid antibodies block b?amyloid fibril formation and prevent b?amyloid?induced neurotoxicity. Brain 126(Pt 9), 1935-1939 (2003).
191. Ma QL, Lim GP, Harris-White ME et al. Antibodies against βamyloid reduce Ab oligomers, glycogen synthase kinase-3b activation and t phosphorylation in vivo and in vitro. J. Neurosci. Res. 83(3), 374-384 (2006).
192. Taguchi H, Planque S, Nishiyama Y et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J. Biol. Chem. 283(52), 4714-4722 (2008).
193. Fillit H, Hess G, Hill J et al. Iv immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 73(3), 180-185 (2009).
194. Kountouris D. Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J. Neural Transm. 5, 18 (2000).
195. Dodel RC, Du Y, Depboylu C et al. Intravenous immunoglobulins containing antibodies against βamyloid for the treatment of Alzheimers disease. J. Neurol. Neurosurg. Psychiatry 75(10), 1472-1474 (2004).
196. Relkin NR, Szabo P, Adamiak B et al. 18?month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 30(11), 1728-1736 (2009).
197. Kayed R, Head E, Thompson JL et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300(5618), 486-489 (2003).
198. Gotz J, Ittner LM. Animal models of Alzheimers disease and frontotemporal dementia. Nat. Rev. Neurosci. 9(7), 532-544 (2008).
199. Meraz-Rios MA, Lira-De Leon KI, Campos- Pena V, De Anda-Hernandez MA, Mena- Lopez R. Tau oligomers and aggregation in Alzheimers disease. J. Neurochem. 112(6), 1353-1367 (2010).
200. Rosenmann H, Meiner Z, Geylis V et al. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimers disease and healthy subjects. Neurosci. Lett. 410(2), 90-93 (2006).
201. Solomon B. Immunological approach for the treatment of Alzheimers disease. J. Mol. Neurosci. 20(3), 283-286 (2003).
202. Taniguchi S, Suzuki N, Masuda M et al. Inhibition of heparin induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280(9), 7614-7623 (2005).
203. Taniguchi T, Sumida M, Hiraoka S et al. Effects of different anti-tau antibodies on tau fibrillogenesis: RTA?1 and RTA?2 counteract tau aggregation. FEBS Lett. 579(6), 1399-1404 (2005).
204. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc. Natl Acad. Sci. USA 97(10), 5129-5134 (2000).
205. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118(4), 658-667 (2011).
206. Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267(1), 564-569 (1992).
207. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential target for immunotherapy for Alzheimer disease and tauopathies. Curr. Alzheimer Res. 8(6), 659-665 (2011).
208. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimers disease related cognitive deficits in transgenic mice. Neuron 45(5), 675-688 (2005).
209. Masliah E, Rockenstein E, Adame A et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46(6), 857-868 (2005).
210. Tampellini D, Magrane J, Takahashi RH et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J. Biol. Chem. 282(26), 18895-18906 (2007).
211. Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 29(43), 13589-13602 (2009).
212. Roberson ED, Scearce-Levie K, Palop JJ et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimers disease mouse model. Science 316(5825), 750-754 (2007).
213. Bateman RJ, Siemers ER, Mawuenyega KG et al. A γsecretase inhibitor decreases amyloidβ production in the central nervous system. Ann. Neurol. 66(1), 48-54 (2009).
214. Castellani RJ, Lee HG, Siedlak SL et al. Reexamining Alzheimers disease: Evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J. Alzheimers Dis. 18(2), 447-452 (2009).
215. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Neuropathology of Alzheimer disease: Pathognomonic but not pathogenic. Acta Neuropathol. 111(6), 503-509 (2006).
216. Lee EB, Leng LZ, Zhang B et al. Targeting amyloidβ peptide (Ab) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Ab precursor protein (APP) transgenic mice. J. Biol. Chem. 281(7), 4292-4299 (2006).
217. Lambert MP, Velasco PT, Chang L et al. Monoclonal antibodies that target pathological assemblies of Ab. J. Neurochem. 100(1), 23-35 (2007).
218. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimers disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007).
219. Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimers disease: A new lexicon. Lancet Neurol. 9(11), 1118-1127 (2010).
220. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimers disease. Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7(3), 263-269 (2011).
221. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimers disease. Recommendations from the National Institute on Aging- Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7(3), 270-279 (2011).
222. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimers disease. Recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7(3), 280-292 (2011).
223. Weiner MW, Aisen PS, Jack CR Jr et al; Alzheimers Disease Neuroimaging Initiative. The Alzheimers disease neuroimaging initiative. progress report and future plans. Alzheimers Dement. 6(3), 202-211 (2010).